Supplement NDI Notification Guidance Cruel To Firms On Animal Testing
This article was originally published in The Rose Sheet
Executive Summary
CFSAN’s latest draft guidance for NDI notifications does little to address the supplement industry’s concerns, and the “worst” aspect is a recommendation to test ingredients on animals when historical use data is not available, says a New Hope Network analyst.
You may also be interested in...
Industry Eyes NDI Notification Common Ground With Gottlieb-Led FDA
CHPA and CRN look forward to working with FDA to develop a path for the identification of pre-DSHEA ingredients, but say the FDA’s revised draft guidance for new dietary ingredient notifications still hampers innovation.
Memebox DTC Whiz To Expand Platform For Korean, In-House Brands
Korean beauty brand-focused Memebox reaches more than 3.3m users with its direct-to-consumer platform, including rapidly growing segments in China and the US. The startup, which just received $66m in new venture funding, leverages social media and celebrity partnerships to drive engagement and sales, while speedily introducing branded product lines of its own.
US House Appropriators Seek Data On Fragrance Allergens In Cosmetics, ‘Balance’ In Sunscreen Regs
The House Appropriations Committee asks the US Food and Drug Administration to provide a report to Congress in two years on the resources it would need to develop a database for fragrance allergens used in cosmetics. The committee’s report accompanying FY2023 FDA funding legislation also touches on OTC sunscreen regulation, PFAS in cosmetics, skin-lightening ingredients, and more.